3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
298
Neoplasms
179
Breast Neoplasms
170
Colorectal Neoplasms
107
Neoplasm Metastasis
100
Melanoma
99
Multiple Myeloma
93
Prostatic Neoplasms
90
Ovarian Neoplasms
83
Recurrence
80
Carcinoma, Renal Cell
73
Lung Neoplasms
71
Stomach Neoplasms
67
Squamous Cell Carcinoma of Head and Neck
67
Lymphoma, Non-Hodgkin
61
Pancreatic Neoplasms
59
Leukemia, Lymphocytic, Chronic, B-Cell
56
Leukemia, Myeloid, Acute
54
Carcinoma, Hepatocellular
48
Triple Negative Breast Neoplasms
47
Small Cell Lung Carcinoma
46
Urinary Bladder Neoplasms
45
Lymphoma, Large B-Cell, Diffuse
43
Head and Neck Neoplasms
41
Endometrial Neoplasms
41
Lymphoma, Follicular
39
Lymphoma
37
Uterine Cervical Neoplasms
35
Parkinson Disease 4, Autosomal Dominant Lewy Body
34
Glioblastoma
34
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
INDUSTRY
×
Unresectable Hepatocellular Carcinoma
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled